AHRQ Director Defends U.S. Preventive Services Task Force
This article was originally published in The Gray Sheet
Executive Summary
Amid wide public outcry over new advice against routine screening for prostate cancer with prostate-specific antigen blood tests, Agency for Healthcare Research and Quality Director Carolyn Clancy is defending both the draft recommendations and the group that issued them, the U.S. Preventive Services Task Force.
You may also be interested in...
News In Brief
Consensus document issued on transcatheter heart valves. Boston Scientific launches Asia-Pacific organization. More news briefs.
Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics
Overdiagnosis and overtreatment of prostate cancers that result from screening with prostate-specific antigen tests highlight the need for research on new diagnostics technologies, suggests a new draft statement from the U.S. Preventive Services Task Force.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.